Galapagos to buy CellPoint, AboundBio to boost access to cell therapies
AboundBio will receive $14m from Galapagos under the agreed transaction.
Belgium
Latest in
Belgium
Oxurion discontinues the development of THR-687 despite promising preclinical data
Oxurion has announced that clinical trials for THR-687, its novel pharmacotherapy for diabetic macular oedema, will not continue.
By
UCB and Microsoft expand drug development partnership
UCB and Microsoft have entered into a new multi-year, strategic collaboration.
Roche and UCB partner to develop antibody therapy for Alzheimer’s
Roche and its unit Genentech have agreed to a global, exclusive licence agreement with Belgian company UCB to develop and…
UCB acquires Engage Therapeutics for $125m
Belgian biopharmaceutical firm UCB has acquired US-based pharmaceutical company Engage Therapeutics for a cash consideration of $125m.
Orionis and Novartis enter drug discovery deal
Life sciences firm Orionis Biosciences has partnered with Novartis to discover and design new drugs for the treatment of a…
Galapagos expands fibrosis research collaboration with Fibrocor
Galapagos has expanded its research collaboration with Candian firm Fibrocor Therapeutics, which develops tissue-specific therapeutics for fibrotic diseases.
Promethera closes Series D funding round to support expansion
Cell-based drugs developer Promethera Biosciences has closed a Series D financing round to support its expansion in Asian markets, along…